Clinical Trial Update: Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis [Phase 2]

View source ↗

Summary

This Phase 2 study reports long-term safety, tolerability, and efficacy data for orally administered BAF312 (siponimod) in patients with Relapsing-Remitting Mul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• BAF312 (siponimod) (siponimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2017-12-12